Literature DB >> 10022011

Comparison of treatment of mastitis by oxytocin or antibiotics following detection according to changes in milk electrical conductivity prior to visible signs.

J E Hillerton1, J E Semmens.   

Abstract

Mastitis was induced in dairy cows by infusion of 500 cfu of Streptococcus uberis into the mammary gland. Most infections developed to clinical disease, and the majority were predicted by changes in the electrical conductivity of the foremilk. The benefits of clinical prognosis and bacteriological cure were determined for cases that were treated when predicted to develop into clinical mastitis and compared with cases that were allowed to develop until milk clotted or until pyrexia before intramammary antibiotic treatment was used. Treatment prior to clinical mastitis included use of intramammary antibiotic or intramuscular oxytocin to allow stripping of residual milk to remove bacteria. All infections in which treatment was delayed resulted in clinical mastitis that was cured clinically and bacteriologically by sustained treatment using a broad-spectrum intramammary antibiotic preparation once daily but requiring a mean treatment time of 10 d. It was possible to prevent clinical mastitis from developing and to eliminate all infections in cows that were treated early when the developing disease was predicted by changes in the electrical conductivity of quarter foremilk and was treated aggressively by administering an intramammary antibiotic at each milking for 3 d. Treatment of 20 IU of oxytocin at six successive milkings of cows that were predicted to develop disease eliminated 25% of the infections, but 75% of the cows developed clinical mastitis. Those cases were resolved by sustained daily treatment using the same intramammary antibiotic. Elimination (100% clinical and bacteriological cure) of all infections caused by Strep. uberis was possible with early and aggressive or sustained use of the intramammary antibiotic. The early intervention using an intramammary antibiotic, when infection was first indicated by changes in the electrical conductivity of milk, was the most efficient method to achieve cure and led to quicker recovery of milk quality to a saleable standard.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10022011     DOI: 10.3168/jds.S0022-0302(99)75213-6

Source DB:  PubMed          Journal:  J Dairy Sci        ISSN: 0022-0302            Impact factor:   4.034


  7 in total

1.  Factors affecting cure when treating bovine clinical mastitis with cephalosporin-based intramammary preparations.

Authors:  A J Bradley; M J Green
Journal:  J Dairy Sci       Date:  2009-05       Impact factor: 4.034

2.  Current management practices and interventions prioritised as part of a nationwide mastitis control plan.

Authors:  P M Down; A J Bradley; J E Breen; C D Hudson; M J Green
Journal:  Vet Rec       Date:  2016-03-10       Impact factor: 2.695

3.  Prediction of Streptococcus uberis clinical mastitis treatment success in dairy herds by means of mass spectrometry and machine-learning.

Authors:  Alexandre Maciel-Guerra; Necati Esener; Katharina Giebel; Daniel Lea; Martin J Green; Andrew J Bradley; Tania Dottorini
Journal:  Sci Rep       Date:  2021-04-08       Impact factor: 4.379

4.  Therapy of Subclinical Mastitis during Lactation.

Authors:  Scott McDougall; Laura M Clausen; Hassan M Hussein; Chris W R Compton
Journal:  Antibiotics (Basel)       Date:  2022-02-07

5.  Physicochemical and adulteration study of fresh milk collected from different locations in Pakistan.

Authors:  Taufiq Nawaz; Zia Ur Rehman; Rafi Ullah; Nazeer Ahmed; Samy Mahmoud Sayed
Journal:  Saudi J Biol Sci       Date:  2022-09-17       Impact factor: 4.052

6.  Factors affecting the cost-effectiveness of on-farm culture prior to the treatment of clinical mastitis in dairy cows.

Authors:  P M Down; A J Bradley; J E Breen; M J Green
Journal:  Prev Vet Med       Date:  2017-07-10       Impact factor: 2.670

7.  Successful treatment of recurrent subclinical mastitis in cows caused by enrofloxacin resistant bacteria by means of the sequential intramammary infusion of enrofloxacin HCl-2H2O and ceftiofur HCl: a clinical trial.

Authors:  Edgar Alfonseca-Silva; Juan Carlos Cruz-Villa; Lilia Gutiérrez; Hector Sumano
Journal:  J Vet Sci       Date:  2021-09-09       Impact factor: 1.672

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.